PTH2

Across TCGA pan-cancer cohorts, PTH2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PTH2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PTH2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTH2 expression acts as an unfavorable survival marker.

LUSC, LIHC, and SKCM are the cancer types where PTH2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.231	0.758	.017	18	view →
LIHC	OS	Median	All	0.198	0.777	.006	18	view →
SKCM	OS	Median	All	0.309	0.788	.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PTH2–LUSC (DFS)

Open the LUSC breakdown →